Methaqualone
psychoactive pharmaceutical
Methaqualone is a sedative-hypnotic medication that was widely prescribed during the mid-20th century. It was marketed under various brand names, including Quaalude ( KWAY-lood) and Sopor, typically containing 300 mg of methaqualone per tablet. A combination drug known as Mandrax was sold primarily in Europe, containing 250 mg of methaqualone and 20 mg of diphenhydramine in a single tablet.
Methaqualone belongs to the quinazolinone class of compounds. Its commercial production was discontinued in many countries during the mid-1980s due to widespread misuse, addiction, and associated public health concerns. However, methaqualone continues to be used as a recreational drug in certain places such as South Africa. In addition, methaqualone analogues with greater than 100-fold potency such as mephenaqualone have emerged as novel designer drugs in the late 2010s and early 2020s.
Medical use
Methaqualone's sedative-hypnotic properties were first identified in 1955. It gained popularity during the 1960s and 1970s for the treatment of insomnia, and as a general sedative and muscle relaxant. However, due to its abuse potential, it was eventually withdrawn from medical use.
Begin with the source’s own compact description: “Methaqualone” is psychoactive pharmaceutical. The dossier treats that line as a proposition to test through Methaqualone, psychoactive and pharmaceutical, not as a finished interpretation.
Why this record matters
The phrase “psychoactive pharmaceutical” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Sep 11, 2026. The linked authority identifier is Q423912. The Library of Congress control number is sh85084387. 1 of 1 selected statements include explicit references; 1 carry qualifiers and 0 use preferred rank. The first chronological checks are 1955.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Methaqualone”, its source revision and the description used here.
- Expand the search: follow Methaqualone primary sources, Methaqualone archive and Methaqualone research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Methaqualone”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Methaqualone” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.